Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 142Leukemia 69Leukemia, Myeloid, Chronic-Phase 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 43Blast Crisis 22Philadelphia Chromosome 14Leukemia, Myeloid, Acute 12Leukemia, Myeloid, Accelerated Phase 12Leukemia, Myeloid 9Leukemia, Myelomonocytic, Chronic 7Primary Myelofibrosis 6Hematologic Neoplasms 6Myeloproliferative Disorders 5Hematologic Diseases 5Bone Marrow Diseases 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hypereosinophilic Syndrome 4Gastrointestinal Stromal Tumors 4Bronchiolitis Obliterans Syndrome 4Recurrence 3Polycythemia Vera 3Neoplasms 3Neoplasm, Residual 3Myelodysplastic Syndromes 3Lymphoma 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3

Interventions

midostaurin 3avapritinib 2ripretinib 1obatoclax 1nilotinib 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Ranitidine 1Interviews as Topic 1Imatinib Mesylate 1Ibuprofen 1Diphenhydramine 1Dexamethasone 1Calcium Dobesilate 1Brentuximab Vedotin 1Azacitidine 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × Imatinib Mesylate × Other hematologic neoplasm × Clear all
NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Novartis

Phase 2 Completed
38 enrolled
MyeloidOther hematologic neoplasmSarcomaThoracic

Lung Neoplasms, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Dermatofibrosarcoma, Mastocytosis, Systemic, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡